Micro-Abstract This study evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among non-Hodgkin lymphoma and multiple myeloma CAR T therapy recipients. In this retrospective study, we evaluated 104 patients that received CAR T therapy; of those 17 patients were evaluated for antibody spike titers following CAR T therapy. We found that only a minority of non-Hodgkin lymphoma and multiple myeloma patients were able to mount a clinically relevant (>250 IU/mL) antibody response.
All Keywords
【저자키워드】 COVID-19 vaccine, lymphoma, cellular therapy, Immunosuppressed, Dysproteinemia,
【저자키워드】 COVID-19 vaccine, lymphoma, cellular therapy, Immunosuppressed, Dysproteinemia,